Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Study Phase : Approved
Recipient : Lipocine
Deal Size : $270.0 million
Deal Type : Licensing Agreement
Lipocine Announces Continued Commercialization of TLANDO® Through Verity Pharmaceuticals
Details : Verity will market TLANDO (testosterone undecanoate), the only oral testosterone replacement therapy indicated for conditions associated with endogenous testosterone deficiency in adult males.
Brand Name : Tlando
Molecule Type : Small molecule
Upfront Cash : $2.5 million
February 02, 2024
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Recipient : Lipocine
Deal Size : $270.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Study Phase : Approved
Recipient : Lipocine
Deal Size : $270.0 million
Deal Type : Licensing Agreement
PharmaTher Updates Its Priority Abbreviated New Drug Application for Ketamine
Details : Under the agreement, Verity Pharma will market Tlando (testosterone undecanoate), the first and only oral testosterone replacement therapy (TRT), in the United States and, if approved, in Canada.
Brand Name : Tlando
Molecule Type : Small molecule
Upfront Cash : $2.5 million
January 18, 2024
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Recipient : Lipocine
Deal Size : $270.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Study Phase : Approved
Recipient : Cumberland Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of that agreement, Cumberland acquired U.S. rights to Sancuso (Granisetron) and assumed full commercial responsibility for the product – including its distribution, marketing, promotion, manufacturing and medical support activities.
Brand Name : Sancuso
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 09, 2022
Lead Product(s) : Granisetron
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Recipient : Cumberland Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Verity Pharma will promote NATESTO across the island of Puerto Rico, leveraging its existing commercial footprint and health care network. Acerus will maintain control of distribution, market access, and regulatory activ...
Brand Name : Natesto
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 10, 2022
Lead Product(s) : Testosterone
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Acerus Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Verity Pharmaceuticals has received a notice of compliance with conditions (NOC/c) from Health Canada for the VERITY-BCG™ (Bacillus Calmette-Guérin [BCG]: Strain Russian BCG-I).
Brand Name : VERITY-BCG
Molecule Type : Large molecule
Upfront Cash : Not Applicable
February 24, 2021
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Study Phase : Approved
Recipient : Debiopharm
Deal Size : Undisclosed
Deal Type : Agreement
Details : The companies have entered into an exclusive agreement that grants Verity Pharmaceuticals Inc. the rights to commercialize Trelstar® (triptorelin pamoate for injectable suspension), a hormone therapy for patients living with prostate cancer.
Brand Name : Trelstar
Molecule Type : Large molecule
Upfront Cash : Undisclosed
June 09, 2020
Lead Product(s) : Triptorelin Pamoate
Therapeutic Area : Oncology
Highest Development Status : Approved
Recipient : Debiopharm
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?
Reset All
